GLP-1 users feel stronger ties to #Health and #Wellness brands
63% of millennials and 61% of Gen Zers feel more connected to health brands since starting GLP-1s
https://content-na1.emarketer.com/glp-1-users-feel-stronger-ties-health-wellness-brands
Recent searches
Search options
#glp1
0 posts0 participants0 posts today
Your brain doesn’t just feel hunger—it negotiates it. Two new circuits reveal the push-pull forces behind every bite. #Neuroscience #WeightLoss #GLP1
https://geekoo.news/how-your-brain-decides-when-to-eat-and-when-to-stop/
GeekooHow Your Brain Decides When to Eat and When to Stop | GeekooRutgers scientists discovered how two brain circuits battle over hunger and fullness—opening the door to smarter weight-loss drugs.
We should talk about what hides under the clinical successes of #glp1 e.g. #tirzepatide or #semaglutide. A paper published in the last 6 months suggests that the benefits (at least as the #kidneys) are concerned are only partly (45%) explained by weight loss. What are we missing?
'The willpower involved is seen as admirable; the idea – which has been debunked by research into obesity – is that anyone can have a slim body, if they only try hard enough. By contrast, using injections to lose weight is perceived as easy, even “lazy"'. https://www.theguardian.com/lifeandstyle/2025/may/11/weight-loss-drugs-why-do-people-lie-about-taking-ozempic #foodstudies #diet #obesity #GLP1 #satiety
The Guardian · ‘I lost so much weight, my husband thought I was terminally ill’: why do people lie about taking Ozempic?
Meghan Rosen: A shadowy market for weight-loss drugs has emerged online. Shortages and big price tags have driven patients to unconventional sources of GLP-1 drugs
"As of February 28, the FDA has received nearly 800 reports of adverse events linked to compounded semaglutide or tirzepatide. These reports aren’t proof of causation, but it’s possible some adverse events may be due to dosing errors. …"
1/2
#GLP1 #weightloss #health #pharmacy
https://www.sciencenews.org/article/weight-loss-drugs-semaglutide-ozempic
Science News · A shadowy market for weight-loss drugs has emerged onlinePeople are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.
https://www.europesays.com/1935241/ Healthcare groups urge FDA to act on compounding regulations after GLP-1 medicine shortages #america #diabetes #education #Entertainment #Food #GLP1 #health #healthcare #medicine #obesity #Semaglutide #sports #UnitedStates #UnitedStatesOfAmerica #US #USA #WeightLoss #Women'sHealth
As someone actively on a GLP-1 as a diabetic, this explainer around the economics of these drugs is both fascinating & maddening.
The Ozempocalypse Is Nigh - by Scott Alexander
https://www.astralcodexten.com/p/the-ozempocalypse-is-nigh
#glp1 #ozempic #semaglutide
Astral Codex Ten · The Ozempocalypse Is Nigh
Continued thread
Some patients in trials for the newest weight-loss drugs are losing ~too much~ weight, eating peanut butter and skipping doses to avoid losing more.
But that conflicts with the industry's hunger for ever-larger weight loss percentages. How are those two interests getting reconciled?
STAT · How much weight loss is too much? Pharma is pushing the limit with new obesity drugsHow much weight loss is too much? Pharma is pushing the limit with new obesity drugs.
Eye doctors at the University of Utah Health and elsewhere published the research, which describes several cases of vision complications possibly tied to these obesity and diabetes drugs. The medications were linked to three different eye conditions, all of which can lead to blindness. But as the doctors caution, the cases alone do not prove that GLP-1 drugs can cause these issues, and more research is needed to understand exactly what’s going on. #health #GLP1 https://gizmodo.com/eye-doctors-are-finding-new-links-between-ozempic-and-vision-problems-2000563080
Gizmodo · Eye Doctors Are Finding New Links Between Ozempic and Vision ProblemsA new case series links GLP-1 use to three different eye conditions, all of which can lead to blindness.
Republicans want you fat, uneducated, starving, and homeless. Call your Republican Senators and Representatives.
GOP sharply divided over coverage of popular weight-loss drugs
https://www.alternet.org/ozempic-gop-semafor/
Alternet.org · GOP sharply divided over coverage of popular weight-loss drugs
Continued thread
Sorry, #dulaglutide med #trulicity; the more general description of these drugs is #glp1 receptor agonists.
Apparently various professional orgs have been kinda all over the map on whether or not to hold such meds pre-op, but now they are coalescing -- still without formal evidence-based guidance, mind you -- around 24-hour liquid diet in preoperative phase, especially for higher doses of the meds for patients on weekly regimens.
Medscape · GLP-1 RAs Safe in the Perioperative Period: New Guidance
Last week @STAT's Katie Palmer had an absolutely bonkers investigation of the few medical groups writing weight-loss GLP-1 drug prescriptions for dozens of telehealth websites.
https://www.statnews.com/2024/10/17/telehealth-online-compounded-glp1-prescriptions-medical-groups/
STAT · How invisible medical groups are powering telehealth’s GLP-1 ‘gold rush’Telehealth sites prescribing GLP-1s online can get off the ground in a matter of days by “renting” the services of these medical groups.
"Some of the benefits appeared to last, however, only as long as patients were taking the drug."
Eli Lilly Says Weight-Loss Drug Sharply Reduces Diabetes Progression
The drug also led to significant weight reduction
Weekly injections of Zepbound for more than 3 years reduced the risk of progression to Type 2 diabetes by 94%, compared with a placebo, among people with excess weight and prediabetes.
:
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management https://www.nature.com/articles/s42255-024-01113-9 #glp1 #semaglutide #tirzepatide #obesity #diabetes #weightloss
NatureGLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management - Nature MetabolismHolst reflects on the development of GLP-1-based drugs for the therapy of obesity, from early observations to remarkable results in more recent clinical trials, discussing physiological, pharmacological and clinical considerations related to their use.
Continued thread
What do drug companies, who only have allegiance to their shareholders, owe to #diabetes patients who literally need these companies to supply something their bodies cannot make?
STAT's Elaine Chen explores what's happening with #insulin and GLP-1s:
https://www.statnews.com/2024/07/17/insuln-novo-nordisk-eli-lilly-weight-loss-drugs/
STAT · As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will move on without themAs GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will leave them in the lurch.
For diabetes patients, GLP-1 drugs linked to lower cancer risks compared to insulin, Ars Technica reports:
https://arstechnica.com/science/2024/07/new-weight-loss-and-diabetes-drugs-linked-to-lower-risk-of-10-cancers/
Ars Technica · New weight-loss and diabetes drugs linked to lower risk of 10 cancersFor diabetes patients, GLP-1 drugs linked to lower cancer risks compared to insulin.
Your gut produces the same thing the GLP-1 weight loss drugs—which make you feel full longer—are trying to mimic, and produces more of it when you eat specific kinds of fiber, like oats, barley, and rye.
Your longread for today: how Mojsov (and many women) get pushed to the margins as history is written, even by close collaborators:
“It was because of Joel and I being friends and talking about science a lot, and me having so much respect for him as a scientist, and my underappreciating what she had done with peptides and not really tuned in that she had her own employment in the endocrine unit.”
https://www.statnews.com/2023/09/27/weight-loss-obesity-glp1-svetlana-mojsov/
STAT · The Ozempic revolution is rooted in the work of Svetlana Mojsov, yet she’s been edged out of the storySvetlana Mojsov, on the discovery of GLP-1: “This is not about me getting prizes. It’s about me actually not being erased from the scientific literature.”
Calling this trial "positive" simply doesn't do it justice.
This is an outrageously positive trial.
I've long been a proponent of #GLP1 as first line for DM. I'd say the same should probably be true for anyone with obesity and an obesity related condition (HTN/DM/HFpEF). I'm even more excited for the more potent agents to be trialed. Primary care is slowly going to evolve into a #GLP1 prescribing.
https://www.nejm.org/doi/full/10.1056/NEJMoa2306963?query=featured_home
“It’s one thing to reach out to physicians and say ‘We’ve got these treatments and they’re so effective and we want you to know about them,’ I don’t think that’s ever going to explain over 100 meals. You just have to laugh, it’s so crazy.”
by (who else but) @STAT's Nick Florko: https://www.statnews.com/2023/07/05/ozempic-rybelsus-novo-nordisk-meals-for-doctors/
STATNovo Nordisk bought prescribers over 450,000 meals and snacks to promote drugs like OzempicNovo Nordisk bought 457,222 meals to educate doctors about its drugs like Ozempic. More than 200 doctors had more than 50 meals with the company.